Treatment for Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Lymphoma
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare two types of chemotherapy to see which is more effective in treating primary CNS B-cell lymphoma.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to 10 years

Up to 10 years
event free survival
number of participants with treatment-related adverse events as assessed by CTCAE v4.0
overall survival
progression free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

113 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 10 years

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
12,990 Previous Clinical Trials
41,297,525 Total Patients Enrolled
1,337 Trials studying Lymphoma
380,516 Patients Enrolled for Lymphoma
Alliance for Clinical Trials in OncologyLead Sponsor
497 Previous Clinical Trials
214,563 Total Patients Enrolled
53 Trials studying Lymphoma
7,069 Patients Enrolled for Lymphoma
Tracy Batchelor, MD, MPHStudy ChairMassachusetts General Hospital
4 Previous Clinical Trials
435 Total Patients Enrolled
2 Trials studying Lymphoma
12 Patients Enrolled for Lymphoma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients must have no prior chemotherapy or radiation therapy for lymphoma.
Documentation of Disease: Diagnosis of primary CNS diffuse large B-cell lymphoma confirmed by one of the following: brain biopsy or resection, cerebrospinal fluid and vitreous fluid.
Patients must have no evidence or history of NHL outside of CNS.
You must be between the ages of 18 and 75 years.
You are a patient who has received a transplant or is on immunosuppressant therapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.